China Regenerative Medicine International Limited provided audited consolidated earnings guidance for the year ended 31 December 2018. For the year, the company expected loss attributable to the shareholders of the company as compared to that for the financial year ended 31 December 2017. Such loss was mainly due to the operation loss for the year, and such loss may further be enlarged by certain impairment loss on goodwill and intangible assets and provision for trade and other receivables.